Literature DB >> 16051735

Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes.

Fanny Rubio-Moscardo1, David Blesa, Cinta Mestre, Reiner Siebert, Theo Balasas, Adalberto Benito, Andreas Rosenwald, Joan Climent, Jose I Martinez, Markus Schilhabel, E Lorraine Karran, Stefan Gesk, Manel Esteller, Ronald deLeeuw, Louis M Staudt, Jose Luis Fernandez-Luna, Daniel Pinkel, Martin J S Dyer, Jose A Martinez-Climent.   

Abstract

Deletions of chromosome 8p are a recurrent event in B-cell non-Hodgkin lymphoma (B-NHL), suggesting the presence of a tumor suppressor gene. We have characterized these deletions using comparative genomic hybridization to microarrays, fluorescence in situ hybridization (FISH) mapping, DNA sequencing, and functional studies. A minimal deleted region (MDR) of 600 kb was defined in chromosome 8p21.3, with one mantle cell lymphoma cell line (Z138) exhibiting monoallelic deletion of 650 kb. The MDR extended from bacterial artificial chromosome (BAC) clones RP11-382J24 and RP11-109B10 and included the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor gene loci. Sequence analysis of the individual expressed genes within the MDR and DNA sequencing of the entire MDR in Z138 did not reveal any mutation. Gene expression analysis and quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) showed down-regulation of TRAIL-R1 and TRAIL-R2 receptor genes as a consistent event in B-NHL with 8p21.3 loss. Epigenetic inactivation was excluded via promoter methylation analysis. In vitro studies showed that TRAIL-induced apoptosis was dependent on TRAIL-R1 and/or -R2 dosage in most tumors. Resistance to apoptosis of cell lines with 8p21.3 deletion was reversed by restoration of TRAIL-R1 or TRAIL-R2 expression by gene transfection. Our data suggest that TRAIL-R1 and TRAIL-R2 act as dosage-dependent tumor suppressor genes whose monoallelic deletion can impair TRAIL-induced apoptosis in B-cell lymphoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16051735     DOI: 10.1182/blood-2005-05-2013

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  Integrative epigenomic and genomic analysis of malignant pheochromocytoma.

Authors:  Johanna Sandgren; Robin Andersson; Alvaro Rada-Iglesias; Stefan Enroth; Goran Akerstrom; Jan P Dumanski; Jan Komorowski; Gunnar Westin; Claes Wadelius
Journal:  Exp Mol Med       Date:  2010-07-31       Impact factor: 8.718

Review 2.  Apoptosis: a review of programmed cell death.

Authors:  Susan Elmore
Journal:  Toxicol Pathol       Date:  2007-06       Impact factor: 1.902

3.  HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells.

Authors:  Carmella Romeo; Matthew C Weber; Mahsa Zarei; Danielle DeCicco; Saswati N Chand; Angie D Lobo; Jordan M Winter; Janet A Sawicki; Jonathan N Sachs; Nicole Meisner-Kober; Charles J Yeo; Rajanikanth Vadigepalli; Mark L Tykocinski; Jonathan R Brody
Journal:  Mol Cancer Res       Date:  2016-04-06       Impact factor: 5.852

Review 4.  Apoptosis and autophagy induction as mechanism of cancer prevention by naturally occurring dietary agents.

Authors:  Eiman Mukhtar; Vaqar Mustafa Adhami; Naghma Khan; Hasan Mukhtar
Journal:  Curr Drug Targets       Date:  2012-12       Impact factor: 3.465

5.  Methyl-CpG-binding domain 3 (Mbd3) is an important regulator for apoptosis in mouse embryonic stem cells.

Authors:  Yujian Dai; Jinshan Li; Mingyang Li; Zhihui Liu; Jiao Liu; Liyou An; Fuliang Du
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

6.  Expression profiles of adult T-cell leukemia-lymphoma and associations with clinical responses to zidovudine and interferon alpha.

Authors:  Ash A Alizadeh; Sean P Bohen; Chen Lossos; Jose A Martinez-Climent; Juan Carlos Ramos; Elena Cubedo-Gil; William J Harrington; Izidore S Lossos
Journal:  Leuk Lymphoma       Date:  2010-07

Review 7.  Risk factors for etiology and prognosis of mantle cell lymphoma.

Authors:  Yu Wang; Shuangge Ma
Journal:  Expert Rev Hematol       Date:  2014-02-22       Impact factor: 2.929

8.  8p21.3 deletion suggesting a probable role of TRAIL-R1 and TRAIL-R2 as candidate tumor suppressor genes in the pathogenesis of multiple myeloma.

Authors:  A Gmidène; A Saad; H Avet-Loiseau
Journal:  Med Oncol       Date:  2013-02-20       Impact factor: 3.064

Review 9.  What can we learn about stroke from retinal ischemia models?

Authors:  Philippe M D'Onofrio; Paulo D Koeberle
Journal:  Acta Pharmacol Sin       Date:  2012-12-03       Impact factor: 6.150

10.  TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis.

Authors:  Niklas Finnberg; Andres J P Klein-Szanto; Wafik S El-Deiry
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.